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Transthyretin V122I in African Americans With Congestive Heart Failure
To the Editor: Hereditary cardiomyopathies are not usually
considered in the diagnosis of elderly individuals with congestive
heart failure (CHF). It is even more problematic in African
Americans, because hypertensive cardiovascular disease is so per-
vasive; however, a large autopsy study showed that above the age of
60 years, transthyretin (TTR) cardiac amyloidosis is more common
in African Americans than in two other ethnic groups (1).
Furthermore, in that analysis more than one-fourth of the African
Americans with TTR cardiac amyloidosis were heterozygous for
an allele encoding isoleucine rather than wild type valine at
position 122 (V122I) in TTR, the serum carrier of retinol binding
protein charged with retinol and a portion of thyroxine. Eighty-
two TTR mutations have been associated with tissue (including
cardiac) amyloid deposition with autosomal dominant inheritance;
V122I is common in African Americans and rare in other
populations (Table 1) (1–3). Very few other variants have been
reported in individuals of African descent.
Because the clinical role of V122I was not established in the
autopsy study and its association with heart disease had been
examined in only a small number of patients with overt cardiac
amyloidosis, we determined its frequency in a cardiologically
well-characterized African-American population with New
York Heart Association (NYHA) functional class III and class
IV CHF participating in the Beta-Blocker Evaluation in
Survival Trial (BEST) (4).
Polymerase chain reaction amplification and restriction diges-
tion of the fourth exon of the TTR gene detected the mutant
codon in 13 (6.28  1.7%) of the 207 African-American BEST
participants, a proportion statistically significantly different from a
sample of African-American newborns in Indiana (p  0.036),
newborns from New York State (p  0.0452), and the African-
American cohort of the Cardiovascular Health Study (CHS) (5) (p
0.004) (Table 1). There were no significant differences in the
distribution of presumed etiologies between the V122I carriers and
homozygous wild type individuals.
Four of the 116 individuals in the under age 60 years cohort (3.5
1.7%) were positive, whereas 9 of the 91 over age 60 years (10 3.1%)
carried the amyloidogenic allele. The difference in prevalence between
the under-60 and over-60 age groups was suggestive but not quite
statistically significant (p 0.08); however, in the over-60 cohort the
prevalence was almost five times that in African Americans of similar
age participating in the community-based CHS; an ascertainment-
bias minimized control population for the over-60 group (10 3.1%
vs. 2.12  0.5%; p 0.0006). The significant difference indicates
the allele is far more prevalent in African Americans with CHF
than in a community cohort of comparable age.
Several features of the BEST study minimize the frequency of
cardiac amyloidosis among the African-American deoxyribonucleic
acid donors. A diagnosis of cardiac amyloidosis was exclusionary.
Moreover, the age distribution in the randomly chosen deoxyribonu-
cleic acid donors differed from that in the entire BEST population
(116 subjects were 59 years or younger, and 91 [44%] were older
among the African-American deoxyribonucleic acid donors; whereas
261 individuals were under 60 years of age, and 366 [58%] were over
60 years of age in the entire African American cohort). Because TTR
cardiac amyloidosis occurs after age 60 years, the age distribution of
the deoxyribonucleic acid donors would tend to reduce the apparent
frequency of heart failure caused by late-onset disease relative to that
in the entire study population (1,6).
The diagnostic echocardiographic studies most likely to distin-
guish cardiac amyloidosis from other causes of CHF were not
performed in all the deoxyribonucleic acid donors. Thus we could
not determine whether amyloidosis played a role in the etiology of
the heart failure. Given the relatively small number of gene
carriers, no survival differences were seen. Furthermore, the pres-
ence of cardiac amyloidosis does not protect the individual from
other forms of heart disease (1).
Multiple studies have shown that cardiac amyloidosis causes
CHF and arrhythmias in older adults; however, these features are
non-specific, and the clinical diagnosis might not be obvious
without careful echocardiographic analysis and endomyocardial
biopsy (6,7). Because we could not perform endomyocardial
biopsies to demonstrate cardiac amyloid deposition pathologically
in any of the V122I carriers, it is formally possible that the allele
imparts risk via some other mechanism. In the earlier autopsy
study there was sufficient clinical information available to ascertain
the presence or absence of CHF in 27 of the 126 subjects with
pathologically established TTR amyloidosis related to either wild
type (both African Americans and Caucasian Americans) or TTR
V122I (African Americans only). In almost one-half of those (13
Table 1. Prevalence of the Amyloidogenic Transthyretin V122I Allele in Individuals Without
Clinically Apparent Amyloidosis
Sample Number Age (yrs) Prevalence (%)
Allele
Frequency
Caucasian (convenience) (2) 86 Not noted 1.2 (0/86) 0.006
Caucasian (3) 453 Newborn 0.4 (2/453) 0.002
African American* 1,219 Newborn 3.3 (40/1219) 0.016
African American (3) 1,000 Newborn 3.0 (30/1000) 0.015
African American (CHS)* 802 Community 65 2.12 (17/802) 0.011
BEST: NYHA class III and IV heart failure* 207 19–93 6.3 (13/207) 0.032
Under age 60 yrs 116 60 3.5 (4/116) 0.018
Age 60 yrs or over 91 60 10 (9/91) 0.05
*Present study.
BEST  Beta-Blocker Evaluation in Survival Trial; CHS  Cardiovascular Health Study; NYHA  New York Heart Association.
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of 27), there was no anatomic evidence of any cardiac disease other
than amyloidosis (1). That study also suggested that the V122I
allele was always associated with some degree of anatomic ventric-
ular amyloid in African Americans 60 years or older and is
consistent with the notion that age-dependent, autosomal domi-
nant cardiac amyloidosis could contribute to congestive failure.
Thus, if the BEST participants were representative of all
African Americans age 60 years or over with NYHA functional
class III and class IV CHF, late onset, autosomal dominant
cardiac amyloidosis due to the TTR V122I allele could be
responsible for 10% of severe heart failure in this population, a
possibility that should be investigated by a more formal study,
rather than as an add-on to a therapeutic trial.
Once considered, the diagnosis is possible by echocardiography
in the majority of cases and by endomyocardial biopsy in all
(subcutaneous fat aspiration might have a low diagnostic yield in
late onset cardiac deposition) (7,8). Although specific therapy is
not available at this time and liver transplantation is denied to
these individuals because of their age, the diagnosis suggests that
digoxin and calcium channel blockers might be avoided (9,10).
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Influence of Proteinuria on Cardiovascular Risk and Response to Angiotensin-Converting
Enzyme Inhibition After Myocardial Infarction
To the Editor: Proteinuria is a known predictor of cardiovascular
(CV) morbidity and mortality in diabetics, hypertensive patients,
and the general population (1–3), but the impact of proteinuria as
a risk factor after acute myocardial infarction (MI) is less well-
defined. We analyzed a subset of patients enrolled in the Survival
And Ventricular Enlargement (SAVE) trial in whom dipstick
urinalyses were recorded to determine the prognostic importance
of baseline proteinuria on outcomes, and to evaluate whether the
response to angiotensin-converting enzyme (ACE) inhibition is
affected by the presence of proteinuria.
The SAVE trial was a randomized, double-blind, placebo-
controlled trial examining the use of ACE inhibition in 2,231 patients
with acute MI and left ventricular dysfunction (left ventricular ejection
fraction [LVEF] 40%) (4). Patients with serum creatinine 2.5
mg/dl were randomized to captopril (50 mg three times a day) or
placebo on average 10 days post-MI. A total of 658 patients from the
Canadian cohort underwent dipstick urinalyses because of safety
concerns, and baseline dipstick measures were available in 583
patients. Dipstick classification included none, trace, 1, 2, 3,
4, corresponding to protein concentrations of10 mg/dl, 10 to 30,
30 to 100, 100 to 300, and 1,000 mg/dl, respectively (5). The
four-variable Modification of Diet in Renal Disease equation was
used to estimate glomerular filtration rate (eGFR) (6). Univariate and
multivariate estimates of risk for outcomes were derived using Cox
proportional hazards models, and the interaction between proteinuria
and treatment effect was assessed. All-cause mortality, CV mortality,
and a composite outcome of death, stroke, recurrent MI, and
hospitalization for congestive heart failure over 42 months of
follow-up were primary end points.
Of 583 subjects, 122 (20.9%) had trace or greater proteinuria
(trace, 14.9%; greater-than-trace, 6.0%). Proteinuric subjects were
older, more often hypertensive (p  0.03), with higher baseline
serum creatinine (p  0.001) Killip class (p  0.001), and lower
LVEF (p  0.001). Diabetes prevalence (p  0.18), use of
lipid-lowering agents (p  0.21), or use of aspirin (p  0.90) did
not significantly differ between patients groups. Proteinuria in-
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